CN118119641A - Ige调节的疾病的治疗 - Google Patents

Ige调节的疾病的治疗 Download PDF

Info

Publication number
CN118119641A
CN118119641A CN202280068465.3A CN202280068465A CN118119641A CN 118119641 A CN118119641 A CN 118119641A CN 202280068465 A CN202280068465 A CN 202280068465A CN 118119641 A CN118119641 A CN 118119641A
Authority
CN
China
Prior art keywords
ige
antibody
seq
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280068465.3A
Other languages
English (en)
Chinese (zh)
Inventor
郭必盛
李昭鋐
李元凤
林淑菁
王长怡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yangzhou Shizhiyuan Biotechnology Co ltd
Original Assignee
United Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United Biomedical Inc filed Critical United Biomedical Inc
Publication of CN118119641A publication Critical patent/CN118119641A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN202280068465.3A 2021-10-12 2022-10-12 Ige调节的疾病的治疗 Pending CN118119641A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163254729P 2021-10-12 2021-10-12
US63/254,729 2021-10-12
PCT/CN2022/124777 WO2023061390A1 (en) 2021-10-12 2022-10-12 Treatment of ige-mediated diseases

Publications (1)

Publication Number Publication Date
CN118119641A true CN118119641A (zh) 2024-05-31

Family

ID=85981469

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280068465.3A Pending CN118119641A (zh) 2021-10-12 2022-10-12 Ige调节的疾病的治疗

Country Status (7)

Country Link
US (1) US20230122862A1 (https=)
EP (1) EP4416176A4 (https=)
JP (1) JP2024538791A (https=)
KR (1) KR20240082392A (https=)
CN (1) CN118119641A (https=)
TW (1) TW202332691A (https=)
WO (1) WO2023061390A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024050455A2 (en) * 2022-08-31 2024-03-07 Heitmeyer Jamie Nicole Anti-rhd antibodies for treating inflammatory dermal condition
WO2025015286A2 (en) * 2023-07-13 2025-01-16 Inhibrx Biosciences, Inc. Ige binding proteins and uses thereof
KR20260042217A (ko) 2023-07-13 2026-03-30 인히브릭스 바이오사이언스, 인크. IgE 결합 단백질 및 이의 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012204078A1 (en) * 2007-02-15 2012-08-02 Astrazeneca Ab Binding members for IgE molecules
KR20140119777A (ko) * 2012-01-31 2014-10-10 제넨테크, 인크. 항-ig-e m1'' 항체 및 그의 사용 방법
DK3157951T3 (da) * 2014-06-17 2020-08-17 Academia Sinica Humaniserede anti-ige-antistoffer, der tværbinder cd23 på b-lymfocytter, men ikke sensibiliserer mastceller
JP6068582B2 (ja) * 2015-08-07 2017-01-25 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ Ｂリンパ球上のヒトｍＩｇＥに結合可能な抗ＣεｍＸ抗体
GB201610198D0 (en) * 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
WO2019085902A1 (en) * 2017-10-31 2019-05-09 Fountain Biopharma Inc. Treating ige-mediated allergic diseases

Also Published As

Publication number Publication date
JP2024538791A (ja) 2024-10-23
WO2023061390A1 (en) 2023-04-20
EP4416176A1 (en) 2024-08-21
TW202332691A (zh) 2023-08-16
KR20240082392A (ko) 2024-06-10
EP4416176A4 (en) 2025-12-31
US20230122862A1 (en) 2023-04-20

Similar Documents

Publication Publication Date Title
US20230357378A1 (en) Use of anti-family with sequence similarity 19, member a5 antibodies for the treatment of neuropathic pain
JP5990701B2 (ja) 治療用イヌ免疫グロブリンおよびそれを用いる方法
JP5969102B2 (ja) 治療用イヌ免疫グロブリンおよびそれを用いる方法
JP7499228B2 (ja) 神経成長因子に対するモノクローナル抗体、並びにそれをコードする遺伝子及びその使用
KR102770849B1 (ko) 향상된 il-6 항체
CA3044851A1 (en) Methods of treating inflammatory conditions
CN118119641A (zh) Ige调节的疾病的治疗
KR20120075457A (ko) 톨-유사 수용체 2에 대한 인간화 항체 및 이의 용도
KR20230078657A (ko) 자가면역 질환 및 암을 치료하기 위한 방법 및 조성물
EP4454659A2 (en) Anti-par-2 antibodies and methods of use thereof
JP2020536495A (ja) 抗ｌａｇ−３抗体及びその使用
CA3077304A1 (en) Anti-pacap antibody
CN108178798B (zh) pH工程化的NGF抗体及其医药用途
EP1972640A1 (en) Apoptosis inducing antibodies
WO2013103783A1 (en) Murine il-13 antibodies
TW202336035A (zh) 治療自體免疫疾病及癌症之方法及組成物
HK40115557A (en) Anti-par-2 antibodies and methods of use thereof
HK40101852A (zh) 治疗自身免疫性疾病和癌症的方法和组合物
HK40027816A (en) Improved il-6 antibodies
HK40102410A (en) Improved il-6 antibodies
HK1244008B (en) Improved il-6 antibodies
HK1195572B (en) Therapeutic canine immunoglobulins and methods of using the same
NZ617450B2 (en) Therapeutic canine immunoglobulins and methods of using the same

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20260104

Address after: 225128 Jiangsu Province Yangzhou City Hanyang District Yangzhou High-tech Industrial Park Health Road No. 2

Applicant after: Yangzhou Shizhiyuan Biotechnology Co.,Ltd.

Country or region after: China

Address before: Hsinchu County, Taiwan, China

Applicant before: UNITED BIOMEDICAL, Inc.

Country or region before: Taiwan, China